Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4471-4476

  Eisenmann, Stephan ^a   Voigt, Wieland ^a   Müller, Thomas ^a   Dempke, Wolfram ^a,b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b Medical Oncology   (Germany)

Author keywords

Cisplatin hypersensitivity; Fractionated X irradiation; Oxaliplatin resistance; Teratoma cell lines

Indexed keywords

CISPLATIN; FAS ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXALIPLATIN; PROTEIN MSH2; PROTEIN P53; SULFORHODAMINE B;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; TERATOMA; WESTERN BLOTTING; X IRRADIATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MUTS HOMOLOG 2 PROTEIN; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TERATOCARCINOMA; TESTICULAR NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 78650241204     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31, 2007.
2. Perez R: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
3. Raymond E, Faivre S, Woynarowski JM and Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25: 4-12, 1998.
4. Lin X and Howell SB: DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5: 1239-1247, 2006.
5. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996.
6. Fink D, Aebi S and Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 4: 1-6, 1998.
7. Dempke W, Voigt W, Grothey A, Hill BT and Schmoll HJ: Cisplatin resistance and oncogenes. Anticancer Drugs 11: 225-236, 2000.
8. Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S and Mezzanzanica D: Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther 2: 762-772, 2007.
9. Hill BT, Whelan RDH, Hosking LK and Lock RB: Interactions between antitumor drugs and radiation in mammalian tumor cells: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro. Natl Cancer Inst Monogr 6: 177-181, 1988.
10. Hill BT, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ and Bedford P: Enhanced DNA repair and tolerance of DNA damage associated with resistacne to cis-diamminedichloroplatinum(II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation. Int J Radiat Oncol Biol Phys 19: 75-83, 1990.
11. Dempke WCM, Shellard SA, Hosking LK, Fichtinger-Schepman AMJ and Hill BT: Mechanisms associated with the expression of cisplatin resistance in a human tumor cell line following exposure to fractionated X-irradiation in vitro. Carcinogenesis 13: 1209-1215, 1992.
12. Dempke WCM, Hosking LA and Hill BT: Expression of collateral sensitivity to cisplatin, methotrexate, and fluorouracil in a human ovarian carcinoma cell line following exposure to fractionated X-irradiation in vitro. Semin Oncol 19: 66-72, 1992.
13. Wang N, Perkins K, Branson D and Farley EE: Cytogenetic evidence for premeiotic transformation of human testicular cancers. Cancer Res 41: 2135-2140, 1981.
14. Casper J, Schmoll HJ, Schnaidt U and Fonatsch C: Cell lines of human germinal cancer. Int J Androl 10: 105-113, 1987
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
16. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
17. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A and Frei E: Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res 46: 4379-4383, 1986.
18. Rixie O, Ortuzar W, Alvarez M, Parker R, Reed E, Pauli K and Fojo T: Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 52: 1855-1861, 1996.
19. Lage H and Dietel M: Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J Cancer Res Clin Oncol 125: 156-165, 1999.
20. Scheef ED, Briggs JM and Howell SB: Molecular modelling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Mol Pharmacol 56: 633-639, 1999.
21. Eichholtz-Wirth H, Stoetzer O and Marx K: Reduced expression of the ICE-related protease CPP32 is associated with radiation-induced cisplatin-resistance in HeLa cells. Br J Cancer 76: 1322-2327, 1997.
22. Eichholtz-Wirth H and Marx K: Clonal variability of radiation-induced cisplatin-resistant HeLa cells. Anticancer Res 18: 2989-2991, 1998.
23. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC and Chaney SG: The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58: 3579-3585, 1998.
24. Sharp SY, O'Neill CF, Rogers P, Boxall FE and Kelland LR: Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 38: 2309-2315, 2002.
25. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF and Jodrell DI: Enhanced oxaliplatin-induced apoptosis following antisense Bcl-x1 down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3: 169-178, 2004.
26. Chao DT and Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 16: 395-419, 1998.
27. El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ and Pendyala L: Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105: 5-14, 1996.
28. Gourdier I, Del Rio M, Crabbe L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y and Pau B: Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529: 232-236, 2002.
29. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S and Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48: 398-406, 2001.
30. Mishima M, Samimi G, Kondo A, Lin X and Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38: 1405-1412, 2002.
31. Stordal BK, Davey MW and Davey RA: Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother Pharmacol 58: 256-265, 2006.
32. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
33. Rennicke A, Voigt W, Mueller T, Frühauf A, Schmoll HJ, Beyer C and Dempke W: Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratoma cell line 2101EP. Anticancer Res 25: 1147-1156, 2005.